Neurofit presented the clinical utility of its brain imaging AI solution at the 63rd American Society of Neuroradiology (ASNR 2025) and announced plans to strengthen collaboration with global pharmaceutical companies and research institutes.
At this conference, Co-CEO Bin Jun-gil participated in the industrial cooperation session and presented the core functions and actual application cases of 'Neurophet AQUA AD', a software that supports the prescription of Alzheimer's disease treatment drugs and monitoring of treatment effects and side effects.
Neurofit Aqua AD quantitatively analyzes MRI (magnetic resonance imaging) and PET (positron emission tomography) images to provide the function of precisely observing Amyloid-Related Imaging Abnormalities (ARIA), which are side effects that may occur during the administration of anti-amyloid antibody treatment.
In addition, Neurofit is introducing its main products, such as 'Neurophet Aqua', a brain nerve degeneration image analysis software, and 'Neurophet SCALE PET', a PET image quantitative analysis software, through its booth exhibition, and is laying the foundation for entering the global market.
Co-CEO Bin Jun-gil said, “Since the global commercialization of Alzheimer’s disease treatment, the importance of ARIA monitoring in clinical settings has been further emphasized,” and “Neurofit Aqua AD is receiving a lot of attention in the field of Alzheimer’s disease clinical image analysis, and through participation in ASNR 2025, we will further strengthen our partnerships with global big pharma and key opinion leaders in the field of neurology.”
- See more related articles
You must be logged in to post a comment.